Vitae Pharmaceuticals is a technology company.
Vitae Pharmaceuticals has raised $79.0M across 4 funding rounds.
Vitae Pharmaceuticals has raised $79.0M in total across 4 funding rounds.
Vitae Pharmaceuticals was a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drugs for diseases with significant unmet needs, including chronic kidney disease, diabetes, Alzheimer's disease, atherosclerosis, autoimmune disorders, atopic dermatitis, and acute coronary syndrome.[1][2][4] It utilized its proprietary Contour® structure-based drug discovery platform to generate potent, selective candidates for "difficult-to-drug" targets, with products like VTP-43742 (Phase I for autoimmune disorders), VTP-38543 (Phase IIa for atopic dermatitis), VTP-34072 (Phase II for type 2 diabetes), and others in development.[2][3][4] The company served patients and served through collaborations with major pharma like Boehringer Ingelheim (BI), addressing challenges in validated but hard-to-target proteins; it built early momentum in AI/ML computational drug discovery before its acquisition by Allergan in September 2016 for $640 million, later operating as a subsidiary of AbbVie.[1][2]
Founded in 2001 in Fort Washington, Pennsylvania, Vitae Pharmaceuticals (originally Concurrent Pharmaceuticals, Inc., renamed in January 2005) emerged from a focus on integrating pre-clinical sciences into an efficient drug discovery platform.[2][3][5] The company was backed by investors like Foresite Capital and Venrock, pursuing novel small molecules for large-market diseases.[4][5] Key early traction came from its Contour® platform, enabling rapid discovery of candidates like those partnered with BI for diabetes (VTP-34072) and Alzheimer's (VTP-37948), leading to a robust pipeline and pivotal acquisition by Allergan in 2016.[1][3]
Vitae rode the wave of structure-based drug design and early computational platforms in biotech, accelerating discovery for challenging targets amid rising demand for precision therapies in metabolic, neurodegenerative, and autoimmune diseases.[3][4] Its timing aligned with the 2000s-2010s shift toward platform-driven biopharma, where tools like Contour® addressed industry struggles with protein structures, influencing the ecosystem by validating SBDD for small molecules and paving the way for AI/ML integration in drug discovery.[1][3] Market forces like unmet needs in diabetes and Alzheimer's favored its approach, with the 2016 Allergan acquisition ($640M) demonstrating VC-backed biotech's role in feeding big pharma pipelines, boosting investor confidence in similar platforms.[1][2]
Post-acquisition, Vitae's assets and expertise integrated into Allergan/AbbVie, with its Contour® legacy enduring through alumni like former CEO Mark Hatfield, who advanced similar innovations at Vividion (acquired by Bayer for $2B total in 2021).[1] Looking ahead, trends in AI-enhanced SBDD and targeted protein degradation (echoed in successors like Gate Bio) will amplify such models, potentially evolving Vitae's influence into sustained contributions via AbbVie's pipeline. This trajectory underscores how nimble platform biotechs like Vitae fuel larger ecosystems, delivering on unmet needs from discovery to patients.
Vitae Pharmaceuticals has raised $79.0M in total across 4 funding rounds.
Vitae Pharmaceuticals's investors include Venrock.
Vitae Pharmaceuticals has raised $79.0M across 4 funding rounds. Most recently, it raised $15.0M Series D in November 2007.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2007 | $15.0M Series D | Venrock | |
| Jul 1, 2005 | $15.0M Series C | Venrock | |
| Jan 1, 2005 | $34.0M Series B | Venrock | |
| Jan 1, 2004 | $15.0M Series B | Venrock |